In recent years, the biotech industry has been one of the more popular sectors for investors, and for good reason too, considering the sort of growth that has been witnessed during the period.
The innovative products that the sector has been churning out for both animal, as well as human health, have generated tremendous growth. This article is going to provide you with a closer look into five biotech stocks that could be worth tracking at this point in time.
At this point in time, the company possesses exclusive licenses for a pair of issued patents and on top of that, it also has control over as many as four provisional patent applications for its extracorporeal treatment for cerebrospinal fluid and blood-related diseases. However, that is not all.
The company has also been using its technology for the purpose of bringing about treatment for a range of other conditions including COVID-19, different forms of cancers, neurological diseases, PTSD, CTE, and others. On the other hand,
It appears that the company's work in the biotech sector has also been noticed by powerful institutions and earlier this month it emerged that
The company's CEO William A Hartman noted at the time that it was also an indication that the company's technology was not of interest to
Alzamend (NASDAQ:ALZN) - Another interesting biotech company that may be of interest to investors at this point in time is Alzamend. The company is a clinical-stage biopharmaceutical firm and is involved in the development of unique products meant for treating diseases like bipolar disorder, Alzheimer's, PTSD, and MOD among others.
At this point in time, the company has a pipeline that is made up of two candidates. One of those is AL001, an ionic cocrystal patented technology that delivers lithium and the other is ALZN002, which is a cell-based therapeutic vaccine that helps patients in fighting Alzheimer's. Considering the work that the company is doing it may be worth tracking further developments.
Biogen (NASDAQ:BIIB) - For much of the year Biogen had been going through tough times. Its Alzheimer's disease product Aduhelm failed and at the same time, the sales of its highly successful multiple sclerosis product Techfidera started facing increasing challenges from generic products. However, the company then staged a remarkable turnaround as it reported positive results from the late stage trial of lecanemab, which is another Alzheimer's product.
The event had taken place in
NASH is currently a widely occurring ailment of the liver and at this point, in time that market is valued in the
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. CaptalGainsReport 'CGR' is responsible for the production and distributions of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has not been compensated to produce and syndicate this content. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website.
585 301 7700
(C) 2022 M2 COMMUNICATIONS, source